文献速递膀胱癌与上尿路尿路上皮癌

EV-301 三期试验:恩诺单抗维多汀对比化疗用于经治晚期尿路上皮癌患者健康相关生活质量

Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy.
PubMed 文献 · Eur Urol · 2024-02-28

EV-301 三期试验中,经治晚期尿路上皮癌患者随机接受恩诺单抗维多汀(EV)或化疗,采用 QLQ-C30 评估健康相关生活质量(HRQoL)。EV 组疼痛改善优于化疗,但食欲下降加重;EV 组多个功能/症状量表确认改善率更高,至确认改善时间更短,至 GHS/QoL 确认恶化时间延迟,但食欲下降恶化更早。

要点

  • EV 组较化疗组疼痛评分变化差异为 -5.7(95%CI -10.8 至 -0.7;p=0.027),食欲下降评分变化差异为 7.3(95%CI 0.90 至 13.69;p=0.026)。
  • EV 组在 10 个 QLQ-C30 功能/症状量表上确认改善的 odds 为化疗组的 1.67 至 2.76 倍。
  • EV 组 GHS/QoL、疲乏、疼痛及躯体、角色、情绪、社会功能至首次确认改善时间均短于化疗组(均 p<0.05)。

核心结论

  • EV 组 HRQoL 得以维持,且较化疗组 HRQoL 恶化延迟;部分量表 EV 组结果更好,疼痛差异最大。

研究设计与样本

  • EV-301 三期试验,患者随机接受 EV 或化疗,采用经验证的 EORTC QLQ-C30 在基线、前 12 周每周、之后每 12 周直至停药进行评估。

主要发现

  • 基线 PRO 依从率 EV 组(n=301)为 91%,化疗组(n=307)为 89%;基线至第 12 周平均依从率分别为 70% 和 67%。
  • EV 组较化疗组疼痛减轻(基线至第 12 周变化差异 -5.7,95%CI -10.8 至 -0.7;p=0.027),食欲下降加重(7.3,95%CI 0.90 至 13.69;p=0.026)。
  • EV 组在 10 个 QLQ-C30 功能/症状量表上确认改善的 odds 为化疗组的 1.67 至 2.76 倍。
  • EV 组 GHS/QoL、疲乏、疼痛及躯体、角色、情绪、社会功能至首次确认改善时间短于化疗组(均 p<0.05)。
  • EV 组 GHS/QoL 至首次确认恶化时间延迟(p=0.027),但食欲下降恶化发生更早(p=0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In comparison to chemotherapy, enfortumab vedotin (EV) prolonged overall survival in patients with previously treated advanced urothelial carcinoma in EV-301. The objective of the present study was to assess patient experiences of EV versus chemotherapy using patient-reported outcome (PRO) analysis of health-related quality of life (HRQoL). METHODS: For patients in the phase 3 EV-301 trial randomized to EV or chemotherapy we assessed responses to the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (QLQ-C30) at baseline, weekly for the first 12 wk, and then every 12 wk until discontinuation. We analyzed the QLQ-C30 change from baseline to week 12, the confirmed improvement rate, and the time to improvement or deterioration. KEY FINDINGS AND LIMITATIONS: Baseline PRO compliance rates were 91% for the EV arm (n = 301) and 89% for the chemotherapy arm (n = 307); the corresponding average rates from baseline to week 12 were 70% and 67%. Patients receiving EV versus chemotherapy had reduced pain (difference in change from baseline to week 12: -5.7, 95% confidence interval [CI] -10.8 to -0.7; p = 0.027) and worsening appetite loss (7.3, 95% CI 0.90-13.69; p = 0.026). Larger proportions of patients in the EV arm reported HRQoL improvement from baseline than in the chemotherapy arm; the odds of a confirmed improvement across ten QLQ-C30 function/symptom scales were 1.67 to 2.76 times higher for EV than for chemotherapy. Patients in the EV arm had a shorter time to first confirmed improvement in global health status (GHS)/QoL, fatigue, pain, and physical, role, emotional, and social functioning (all p < 0.05). EV delayed the time to first confirmed deterioration in GHS/QoL (p = 0.027), but worsening appetite loss occurred earlier (p = 0.009) in comparison to chemotherapy. CONCLUSIONS AND CLINICAL IMPLICATIONS: HRQoL with EV was maintained, and deterioration in HRQoL was delayed with EV in comparison to chemotherapy. Better results with EV were reported for some scales, with the greatest difference observed for pain. These findings reinforce the EV safety and efficacy outcomes and benefits observed in EV-301. PATIENT SUMMARY: Patients with previously treated advanced cancer of the urinary tract receiving the drug enfortumab vedotin maintained their HRQoL in comparison to patients treated with chemotherapy. The EV-301 trial is registered on ClinicalTrials.gov as NCT03474107 and on EudraCT as 2017-003344-21.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Rosenberg JE, Mamtani R, Sonpavde GP, et al. Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy. Eur Urol. 2024. PMID: 38418343. doi:10.1016/j.eururo.2024.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。